VDN-0100 / Vedana Therapeutics - LARVOL DELTA

Vedana Therapeutics Launches With $46 Million Series A Financing to Advance Next-Generation Migraine Therapies (Businesswire) - "Proceeds from the financing will be used to advance Vedana's portfolio of internally discovered, potentially best-in-class, subcutaneously delivered antibodies targeting clinically validated pathways for migraine prevention...The company's lead program is the next-generation anti-PACAP antibody, and its second program targets both PACAP and CGRP."

Financing • Migraine